MeSH D015497 - hiv-1
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Merck & Co | Doravirine, Tenofovir disoproxil, Lamivudine | Delstrigo | 2032-08-30 | 2018-08-30 | $260 M | Q2/24-Q1/25 |
| Doravirine | Pifeltro | 2032-08-30 | 2018-08-30 | $166 M | Q2/24-Q1/25 |
Clinical Trials
Historical Success Rate
Phase 1
90%9/10
Phase 2
75%12/16
Phase 3
71%12/17
Approved: 1Overall Success rate: 48%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use